These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 118937

  • 1. Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasms.
    Mathieu L, Chevalier P, Galy G, Berger M.
    Int J Appl Radiat Isot; 1979 Dec; 30(12):725-7. PubMed ID: 118937
    [No Abstract] [Full Text] [Related]

  • 2. 99mTc-labelled Cu(I)-EHDP, a potential skeletal imaging agent.
    Agha NH, Al-Hilli AM, Hassen HA.
    Nuklearmedizin; 1981 Dec; 20(6):299-304. PubMed ID: 6799937
    [Abstract] [Full Text] [Related]

  • 3. Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma.
    De Winter F, Brans B, Van De Wiele C, Dierckx RA.
    Clin Nucl Med; 1999 Nov; 24(11):898-9. PubMed ID: 10551482
    [No Abstract] [Full Text] [Related]

  • 4. [Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP].
    Hauswirth AE, Palmedo H, Dierke-Dzierzon C, Biersack HJ, Krebs D.
    Zentralbl Gynakol; 1998 Nov; 120(2):83-6. PubMed ID: 9531713
    [Abstract] [Full Text] [Related]

  • 5. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
    ter Heine R, Lange R, Breukels OB, Bloemendal HJ, Rummenie RG, Wakker AM, de Graaf H, Beekman FJ, van der Westerlaken MM, Malingré MM, Wielders JP, van den Berg L, Hendrikse NH, de Klerk JM.
    Int J Pharm; 2014 Apr 25; 465(1-2):317-24. PubMed ID: 24560635
    [Abstract] [Full Text] [Related]

  • 6. Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP.
    Palmedo H, Grünwald F, Wagner U, Köhler S, Krebs D, Biersack HJ.
    Clin Nucl Med; 1998 Aug 25; 23(8):501-4. PubMed ID: 9712380
    [Abstract] [Full Text] [Related]

  • 7. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer.
    Limouris G, Shukla SK, Manetou A, Kouvaris I, Plataniotis G, Triantafyllou N, Rigas AV, Vlahos L.
    Anticancer Res; 1997 Aug 25; 17(3B):1699-704. PubMed ID: 9179222
    [Abstract] [Full Text] [Related]

  • 8. Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
    Scher HI, Curley T, Yeh S, Tong W, O'Moore PV, Larson S.
    Adv Exp Med Biol; 1992 Aug 25; 324():115-29. PubMed ID: 1283494
    [No Abstract] [Full Text] [Related]

  • 9. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
    Liepe K, Geidel HH, Bergmann R, Haase M, Runge R, Kotzerke J.
    Nucl Med Commun; 2009 Sep 25; 30(9):693-9. PubMed ID: 19528873
    [Abstract] [Full Text] [Related]

  • 10. Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
    Liepe K, Kropp J, Hliscs R, Franke WG.
    Clin Nucl Med; 2000 Nov 25; 25(11):901-4. PubMed ID: 11079588
    [Abstract] [Full Text] [Related]

  • 11. Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases.
    Palmedo H, Bender H, Dierke-Dzierzon C, Carl UM, Risse J, Krebs D, Biersack HJ.
    Clin Nucl Med; 1999 Sep 25; 24(9):643-8. PubMed ID: 10478737
    [Abstract] [Full Text] [Related]

  • 12. Imaging of bone metastases with 99m Tc-Sn-EHDP (diphosphonate), 18 F, and skeletal radiography. A comparison of sensitivity.
    Silberstein EB, Saenger EL, Tofe AJ, Alexander GW, Park HM.
    Radiology; 1973 Jun 25; 107(3):551-5. PubMed ID: 4633984
    [No Abstract] [Full Text] [Related]

  • 13. Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
    Silberstein EB.
    J Nucl Med; 1996 Feb 25; 37(2):249-52. PubMed ID: 8667054
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
    Maxon HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, Smith H, Moulton JS, Williams CC, Ehrhardt GJ.
    J Nucl Med; 1991 Oct 25; 32(10):1877-81. PubMed ID: 1717669
    [Abstract] [Full Text] [Related]

  • 17. Preparation of 186Re-perrhenate for nuclear medical purposes.
    Eisenhut M.
    Int J Appl Radiat Isot; 1982 Feb 25; 33(2):99-103. PubMed ID: 7061167
    [Abstract] [Full Text] [Related]

  • 18. Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.
    Graham MC, Scher HI, Liu GB, Yeh SD, Curley T, Daghighian F, Goldsmith SJ, Larson SM.
    Clin Cancer Res; 1999 Jun 25; 5(6):1307-18. PubMed ID: 10389913
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.
    Lin WY, Lin CP, Yeh SJ, Hsieh BT, Tsai ZT, Ting G, Yen TC, Wang SJ, Knapp FF, Stabin MG.
    Eur J Nucl Med; 1997 Jun 25; 24(6):590-5. PubMed ID: 9169563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.